Share on StockTwits

Shares of Rexahn Pharmaceuticals (NYSE:RNN) saw a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 5,972,040 shares, a decrease of 2.8% from the July 31st total of 6,141,290 shares, Stock Ratings Network reports. Based on an average daily volume of 574,751 shares, the short-interest ratio is currently 10.4 days. Approximately 3.5% of the company’s stock are sold short.

Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.70 on Thursday. Rexahn Pharmaceuticals has a one year low of $0.36 and a one year high of $1.85. The stock’s 50-day moving average is $0.72 and its 200-day moving average is $0.95. The company’s market cap is $124.8 million.

Rexahn Pharmaceuticals (NYSE:RNN) last announced its earnings results on Thursday, August 14th. The company reported ($0.02) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.02). Analysts expect that Rexahn Pharmaceuticals will post $-0.14 EPS for the current fiscal year.

Rexahn Pharmaceuticals, Inc (NYSE:RNN) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide.

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.